Genus Capital Management’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.78M Sell
3,280
-6,835
-68% -$3.53M 0.18% 138
2026
Q2
$5.48M Buy
10,115
+1,230
+14% +$693K 0.54% 58
2026
Q1
$5.27M Buy
8,885
+4,445
+100% +$2.21M 0.6% 56
2025
Q4
$2.16M Buy
+4,440
New +$2.07M 0.25% 98

Other funds holding UTHR

Genus Capital Management's UTHR Position: Q3 2026 in Review

Genus Capital Management reduced its United Therapeutics (UTHR) stake by 68% in Q3 2026, selling an estimated $3.53M and leaving 3,280 shares worth $1.78M. The position accounts for 0.18% of the portfolio, ranked #138.

Genus Capital Management first reported a position in UTHR in Q4 2025 and has held it in 4 quarters since. The position peaked at $5.48M in Q2 2026. 838 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • Genus Capital Management held 3,280 shares of United Therapeutics worth $1.78M as of Q3 2026.
  • Genus Capital Management sold 6,835 United Therapeutics shares in Q3 2026, an estimated $3.53M.
  • United Therapeutics made up 0.18% of Genus Capital Management's portfolio in Q3 2026, its #138 holding.
  • Genus Capital Management first reported a position in United Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Genus Capital Management's United Therapeutics position peaked at $5.48M in Q2 2026.
  • 838 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Genus Capital Management's 13F filing for Q3 2026, filed 4 Nov 2026.